Open AccessHealth‐related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ‐5D: A multicenter cross‐sectional study
Author(s) -
Wang Youqing,
Shi Jufang,
Du Lingbin,
Huang Huiyao,
Wang Le,
Zhu Juan,
Li Huizhang,
Bai Yana,
Liao Xianzhen,
Mao Ayan,
Liu Guoxiang,
Ren Jiansong,
Sun Xiaojie,
Gong Jiyong,
Zhou Qi,
Mai Ling,
Zhu Lin,
Xing Xiaojing,
Liu Yuqin,
Ren Ying,
Song Bingbing,
Lan Li,
Zhou Jinyi,
Lou Peian,
Sun Xiaohua,
Qi Xiao,
Wu Shouling,
Wei Wenqiang,
Zhang Kai,
Dai Min,
Chen Wanqing,
He Jie
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13368
Subject(s) - medicine , quality of life (healthcare) , cross sectional study , eq 5d , stage (stratigraphy) , visual analogue scale , pathological , cancer , health related quality of life , esophageal cancer , oncology , physical therapy , pathology , disease , paleontology , nursing , biology
Background We aimed to obtain a set of health state utility scores of patients with esophageal cancer (EC) and precancerous lesions in China, and to explore the influencing factors of health‐related quality of life (HRQoL). Methods A hospital‐based multicenter cross‐sectional study was conducted. From 2013 to 2014, patients with EC or precancerous lesions were enrolled. HRQoL was assessed using a European quality of life‐5 dimension (EQ‐5D‐3L) instrument. Multivariable linear regression analysis was performed to explore the influencing factors of the EQ‐5D utility scores. Results A total of 2090 EC patients and 156 precancer patients were included in the study. The dimension of pain/discomfort had the highest rate of self‐reported problems, 60.5% in EC and 51.3% in precancer patients. The mean visual analog scale (VAS) score for EC and precancer patients were 68.4 ± 0.7 and 64.5 ± 3.1, respectively. The EQ‐5D utility scores for EC and precancer patients were estimated as 0.748 ± 0.009 and 0.852 ± 0.022, and the scores of EC at stage I, stage II, stage III, and stage IV were 0.693 ± 0.031, 0.747 ± 0.014, 0.762 ± 0.015, and 0.750 ± 0.023, respectively. According to the multivariable analyses, the factors of region, occupation, household income in 2012, health care insurance type, pathological type, type of therapy, and time points of the survey were statistically associated with the EQ‐5D utility scores of EC patients. Conclusions There were remarkable decrements of utility scores among esophageal cancer patients, compared with precancer patients. The specific utility scores of EC would support further cost‐utility analysis in populations in China.